United States Opioid Analgesics Market Assessment, By Product Type [Codeine, Morphine, Oxycodone, Hydrocodone, Methadone, Meperidine, Fentanyl, Hydromorphone, Oxymorphone, Dextromethorphan, Tramadol, Others], By Route of Administration [Oral, Injectable, Others], By Application [Chronic Pain, Acute Pain], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Others], By Region, Opportunities and Forecast, 2018-2032F

United States opioid analgesics market is projected to witness a CAGR of 3.64% during the forecast period 2025-2032, growing from USD 12.16 billion in 2024 to USD 16.15 billion in 2032.

United States Opioid Analgesics Market, Size, Future, Growth & Forecast 2032

United States opioid analgesics market&nbsp;is projected to witness a&nbsp;CAGR of 3.64%&nbsp;during the forecast period 2025-2032, growing from&nbsp;USD 12.16 billion&nbsp;in 2024 to&nbsp;USD 16.15 billion&nbsp;in 2032. The growth of the aging population, rising prevalence of chronic diseases, and increasing requirement for products that aid in management of post-operative pain are some of the major factors driving the growth of the opioid analgesics market in the United States. According to the estimates of the Population Reference Bureau, the number of Americans that are 65 and older is expected to witness a 47% increase from 2022 to 2050.
<table>
<tbody>
<tr>
<td width="301">
Report Attribute
</td>
<td width="301">
Details
</td>
</tr>
<tr>
<td width="301">
Base Year of the Analysis
</td>
<td width="301">
2024
</td>
</tr>
<tr>
<td width="301">
Historical Period
</td>
<td width="301">
2018-2023
</td>
</tr>
<tr>
<td width="301">
Forecast Period
</td>
<td width="301">
2025-2032F
</td>
</tr>
<tr>
<td width="301">
Projected Growth Rate
</td>
<td width="301">
CAGR of 3.64% between 2025 and 2032
</td>
</tr>
<tr>
<td width="301">
Revenue Forecast in 2032
</td>
<td width="301">
USD 16.15 billion
</td>
</tr>
</tbody>
</table>
The market&rsquo;s growth is also supported by the strong presence of major market players, continuous investments in research and developments activities, and increasing healthcare expenditure in the United States. Research institutions and healthcare organizations are focusing on developing safer opioid alternatives and in post-marketing surveillance to monitor adverse events. Additionally, the United States continues to witness increase in the number of surgical procedures, further driving the demand for opioids in acute care setting.
Expansion of the Aging Population Boosts Market Demand
The rapid growth of the aging population is one of the major drivers of the market as the elderly are more prone to age-related chronic conditions such as neuropathic pain and arthritis, among others. In such conditions, the patients often rely on effective pain management solutions, resulting in a higher requirement for opioid analgesics. Additionally, the older population is also more likely to undergo surgical procedures, frequently necessitating postoperative pain relief. They are also susceptible to injuries and degenerative diseases, further amplifying the requirement for potent pain relief solutions. As per the estimates of the Christopher &amp; Dana Reeve Foundation, approximately 18,000 new spinal cord injuries are reported every year in the United States.
Meanwhile, pharmaceutical companies and healthcare professionals are increasingly focusing on personalized medicines and customized pain management strategies in order to align with the unique pain management requirements of the older population.
Increasing Focus on Abuse-Deterrent Formulations (ADFs) Supports Market Expansion
The focus on developing ADFs has significantly increased over the past few years in order to address the ongoing opioid crisis by maintaining the pain relief benefits of opioids for genuine patients while reducing the potential for abuse. The Food and Drug Administration (FDA) is actively encouraging the development and introduction of ADFs, promoting collaborations among specialty pharmaceutical companies. For instance, in March 2025, Protega Pharmaceuticals Inc. and Wellgistics Health partnered with each other to enhance pharmacist education and improve patient access to ROXYBOND, the first and only FDA-approved abuse-deterrent immediate-release opioid in the United States. Such initiatives are directed towards addressing the more complicated issue of pain management and opioid prescribing and seek to promote safer opioid utilization and reduce the risks associated with opioid use.
Mergers and Acquisitions Drive Market Growth
Such strategic initiatives are allowing leading pharmaceutical companies to improve their research and development capabilities, expand their product portfolios, and strengthen their market presence. Additionally, pharmaceutical giants are also focusing on mergers and acquisitions due to the major financial challenges faced by various companies during the opioid crisis and opioid-related litigation. For instance, in March 2025, Mallinckrodt Pharmaceuticals plc and Endo Pharmaceuticals Inc. announced a USD 6.7 billion merger that is expected to close in the second half of 2025. Both companies have faced financial challenges due to opioid-related litigation and are seeking to create a more resilient pharmaceutical entity with enhanced resources for innovation and growth, with this merger. This collaboration is also expected to enhance their financial stability and strengthen their position in the market.
Retail Pharmacies Hold Major Market Share
Due to their accessibility, extensive reach, and role in dispensing prescription medications, retail pharmacies hold a major share in the United States opioid analgesics market. These pharmacies serve as the primary distribution channel for opioid analgesics for patients suffering from chronic pain, among other medical conditions. Additionally, patients also prefer retail pharmacies due to their convenient nature. Retail pharmacies cater to patients across all regions, including those living in rural and underserved areas. Additionally, retail pharmacies play a vital role in ensuring compliance for opioid use with regulatory guidelines. They are able to monitor prescriptions and dispense the proper dosages while providing counseling to patients regarding the use of opioids. Thus, bolstering the segment&rsquo;s expansion.
<a href="https://www.marketsandata.com/industry-reports/united-states-opioid-analgesics-market/sample-request">Download Free sample Report</a>
Future Market Scenario (2025 &ndash; 2032F)
The United States opioid analgesics market is expected to witness significant growth in the coming years, driven by rising demand for the treatments for acute and chronic pain, advancements in formulations, and increasing awareness about responsible opioid use. While the opioid epidemic is a major challenge, collaborative industry and regulatory efforts are supporting the market&rsquo;s revival. Increasing focus on dual-action painkillers, utilization of biosensors for personalized pain management therapy, and artificial intelligence for prescription management are expected to provide lucrative growth opportunities for the market.
Report Scope
&ldquo;United States&nbsp;Opioid Analgesics&nbsp;Market&nbsp;Assessment, Opportunities and Forecast, 2018-2032F&rdquo;,&nbsp;is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of United States opioid analgesics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
<table>
<tbody>
<tr>
<td width="301">
Report Attribute
</td>
<td width="301">
Details
</td>
</tr>
<tr>
<td width="301">
Segments Covered
</td>
<td width="301">
Product Type, Route of Administration, Application, Distribution Channel
</td>
</tr>
<tr>
<td width="301">
Regions Covered
</td>
<td width="301">
Northeast, Midwest, West, South
</td>
</tr>
<tr>
<td width="301">
Key Companies Profile
</td>
<td width="301">
Pfizer Inc., Teva Pharmaceuticals Industries Ltd., Endo Pharmaceuticals Inc., Sanofi S.A., Daiichi Sankyo, Inc., Hikma Pharmaceuticals USA Inc., Purdue Pharma L.P., Mundipharma Pty Limited, Protega Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals plc
</td>
</tr>
<tr>
<td width="301">
Customization Scope
</td>
<td width="301">
15% free report customization with purchase
</td>
</tr>
<tr>
<td width="301">
Pricing and Purchase Options
</td>
<td width="301">
Avail the customized purchase options to fulfill your precise research needs
</td>
</tr>
<tr>
<td width="301">
Delivery Format
</td>
<td width="301">
PDF and Excel through email (subject to the license purchased)
</td>
</tr>
</tbody>
</table>
In the report,&nbsp;United States&nbsp;opioid analgesics&nbsp;market&nbsp;has been segmented into the following categories:&nbsp;
<ul>
<li>By Product Type
<ul>
<li>Codeine</li>
<li>Morphine</li>
<li>Oxycodone</li>
<li>Hydrocodone</li>
<li>Methadone</li>
<li>Meperidine</li>
<li>Fentanyl</li>
<li>Hydromorphone</li>
<li>Oxymorphone</li>
<li>Dextromethorphan</li>
<li>Tramadol</li>
<li>Others</li>
</ul>
</li>
<li>By Route of Administration
<ul>
<li>Oral</li>
<li>Injectable</li>
<li>Others</li>
</ul>
</li>
<li>By Application
<ul>
<li>Chronic Pain</li>
<li>Acute Pain</li>
</ul>
</li>
<li>By Distribution Channel
<ul>
<li>Hospital Pharmacies</li>
<li>Retail Pharmacies</li>
<li>Others</li>
</ul>
</li>
<li>By Region
<ul>
<li>Northeast</li>
<li>Midwest</li>
<li>West</li>
<li>South</li>
</ul>
</li>
</ul>
Key Players Landscape and Outlook
The new tariffs in the United States are significantly impacting the market, with leading players focusing on shifting their manufacturing operations to the United States. In March 2025, Pfizer Inc. announced plans to move its manufacturing operations to the United States, leveraging its existing 13 United States production plants, including production facilities for antibodies and sterile injectables.
The market players are also focusing on introducing new products in order to maintain their position in the industry. For instance, In February 2024, Hikma Pharmaceuticals USA Inc. launched Fentanyl Citrate Injections, USP, in 25mcg/0.5mL and 50mcg/mL doses. The product has been launched in the United States and is indicated for short-duration analgesic action, premedication, induction, and maintenance, as well as in the immediate postoperative period as per the patient requirement.
Key Players Operating in the United States&nbsp;Opioid Analgesics&nbsp;Market&nbsp;are:
<ul>
<li>Pfizer Inc.</li>
<li>Teva Pharmaceuticals Industries Ltd.</li>
<li>Endo Pharmaceuticals Inc.</li>
<li>Sanofi S.A.</li>
<li>Daiichi Sankyo, Inc.&nbsp;</li>
<li>Hikma Pharmaceuticals USA Inc.</li>
<li>Purdue Pharma L.P.</li>
<li>Mundipharma Pty Limited</li>
<li>Protega Pharmaceuticals Inc.</li>
<li>Mallinckrodt Pharmaceuticals plc</li>
</ul>
If you can't find what you're searching for or have any custom requirements for the&nbsp;United States&nbsp;opioid analgesics&nbsp;market, you may approach our team at&nbsp;<a href="mailto:info@marketsandata.com">info@marketsandata.com</a>

United States Opioid Analgesics Market Assessment, Opportunities and Forecast, 2018-2032F

The growth of the market is supported by the rising prevalence of chronic diseases, increasing requirement for surgical procedures, and expansion of the aging population.

FAQs

Industry Reports

Blogs

Case Studies

Industry News

Press Release

Infographics